Description
Zoledronic Acid Accord 4 mg/5 ml concentrate for solution for infusion
Contents: Zoledronic acid.
Description: Each 5 mL contains: Zoledronic acid monohydrate eq. to Zoledronic acid anhydrous 4 mg.Water for injections Ph. Eur. Q.S. to 5 mL.
Pharmacology:
Pharmacodynamics: Zoledronic acid belongs to the class of bisphosphonates and acts primarily on bone. It is an inhibitor of osteoclastic bone resorption. The selective action of bisphosphonates on bone is based on their affinity for mineralised bone, but the precise molecular mechanism leading to the inhibition of osteoclastic activity is still unclear. In long-term animal studies, zoledronic acid inhibits bone resorptio without adversely affecting the formation, mineralisation or mechanical prorpertie of bone. In addition to being a potent inhibitor of bone resorption, zoledronic acid also possesses several anti-tumour properties that could contribute to its overall efficacy in the treatment of metastatic bone disease.
The following properties have been demonstrated in preclinical studies:
In vivo: Inhibition of osteoclastic bone resorption, which alters the bone marrow microenvironment , making it less conducive to tumour cell growth, anti-angiogenic activity and anti-pain activity.
In vitro: Inhibition of osteoblast proliferation, direct cytostatic and pro-apoptotic on tumour cells, synergistic cytostatic effect with other anti-cancer drugs, anti-adhesion/invasion activity.
